Çocukluk Çağı Hodgkin Lenfomalarında CD163 Ekspresyonunun Prognostik Önemi

ÖZ Amaç: Bu çalışmanın amacı, pediatrik Hodgkin lenfoma olgularında CD163 ekspresyonunun prognozla ilişkisini incelemektir. Materyal-metod: Bu çalışmaya retrospektif olarak; Ocak 2014- Aralık 2020 tarihleri arasında Sağlık Bilimleri Üniversitesi Prof. Dr. Cemil Taşcıoğlu Şehir Hastanesi Pediatrik Onkoloji ve Hematoloji Klinikleri’nde Hodgkin Lenfoma (HL) tanısı ile tedavi ve takipleri yapılan 0-18 yaş aralığındaki, 21 pediatrik hasta dahil edildi. Olguların ilk tanı biyopsilerine CD163 immünhistokimyası uygulandı. CD163 ekspresyonlarına göre ; %25 olmak üzere 3 gruba ayrıldı. Bulgular: Olguların yaşları 6 ile 17 arasında değişmekte olup %4,8’i (n=1) Evre 1, %28,6’sı (n=6) Evre 2, %33,3’ü (n=7) Evre 3, %33,3’ü (n=7) Evre 4 olarak tanı almıştır. Olguların %42,9’unda (n=9) B semptomu, %15’inde (n=3) progresyon, %38’inde (n=8) dalak tutulumu mevcuttur. Histolojik subtip dağılımları; %4,8 (n=1) lenfositten fakir tip, %33,3 (n=7) mikst selüler tip, %4,8 (n=1) nodüler lenfosit predominant HL, %57,1 (n=12) nodüler sklerozan tip şeklindedir. CD 163 ekspresyon değerleri incelendiğinde, olguların %38,1’inin (n=8) %5’in altında, %33,3’ünün (n=7) %5-25 aralığında, %28,6’sının (n=6) >%25 olduğu görülmektedir. CD163 ekspresyon gruplarına göre olguların cinsiyetleri, yaşları evreleri, B semptomu varlığı, progresyon durumu, histolojik subttipler ve dalak tutulumu açısından istatistiksel olarak anlamlı farklılık göstermemektedir (p>0,05). Sonuç: CD163 ekspresyonun pediatrik HL olgularında prognostik öneminin anlaşılması için daha kapsamlı araştırmalar gerekmektedir.

The Prognostic İmpact of CD163 Expression in Childhood Hodgkin Lypmhomas

Aim: The aim of this studay is to examine the relationship betwen CD163 expression and prognosis in pediatrik Hodgkin lymphoma cases. Material-methods: In this study retrospectively; twenty-one pediatric patients were included who were treated and followed-up with the diagnosis of Hodgkin Lymphoma (HL) in the Pediatric Oncology and Hematology Clinics of Prof. Dr. Cemil Taşcıoğlu City Hospital, between January 2014 and December 2020. CD163 immunohistochemistry was applied to the initial diagnostic biopsies of the cases. Results: The ages of the cases ranged from 6 to 17, with 4.8% (n=1) Stage 1, 28.6% (n=6) Stage 2, 33.3% (n=7) Stage 3, 33.3% (n=7) were diagnosed as Stage 4. B symptoms were present in 42.9% (n=9) of the cases, progression in 15% (n=3), and spleen involvement in 38% (n=8). Histological subtype distributions; 4.8% (n=1) lymphocyte-poor type, 33.3% (n=7) mixed cellular type, 4.8% (n=1) nodular lymphocyte predominant HL, 57.1% (n=12) nodular sclerosing type. When CD 163 expression values were examined, 38.1% (n=8) of the cases were below 5%, 33.3% (n=7) were between 5-25%, 28.6% (n=7) were 6) It is seen that it is >25%. According to CD163 expression groups, there was no statistically significant difference in terms of gender, age, stage, presence of B symptoms, progression status, histological subtypes and spleen involvement (p>0.05). Conclusion: More extensive studies are required to understand the prognostic significance of CD163 expression in pediatric HL cases.

___

1. Chang ET, Zheng T, Weir EG, Borowitz M, Mann RB, Spiegelman D et al. Childhood social environment and Hodgkin's lymphoma: new findings from a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2004 Aug; 13(8):1361-70.

2. Punnett A, Tsang RW, Hodgson DC. Review Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects. Semin Radiat Oncol. 2010 Jan; 20(1):30-44.

3.Werner, L., Dreyer, J.H.; Hartmann, D, Barros, M.H.M, Büttner-Herold, M, Grittner, U et al. Tumor-associated macrophages in classical Hodgkin lymphoma: Hormetic relationship to outcome. Sci. Rep. 2020, 10, 1–11.

4.He, W, Kapate, N, Shields, C.W, Mitragotri S. Drug delivery to macrophages: A review of targeting drugs and drug carriers to macrophages for inflammatory diseases. Adv. Drug Deliv. Rev. 2019.

5.Cassetta, L, Pollard, J.W. Targeting macrophages: Therapeutic approaches in cancer. Nat. Rev. Drug Discov. 2018, 17, 887–904.

6. Harris J.A, Jain S, Ren Q, Zarineh A, Liu C, Ibrahim S. CD163 versus CD68 in tumor asociated macrophages of classical hodgkin lymphoma. Diagnostic Pathology 2012, 7:12.

7. Kristiansen M, Graversen J.H, Jacobsen, C, Sonne O, Hoffman H.-J, Law S.A. et al. Identification of the haemoglobin scavenger receptor. Nature 2001, 409, 198–201.

8. Guo L, Akahori H, Harari E, Smith S.L, Polavarapu R, Karmali V et al. CD163+ macrophages promote angiogenesis and vascular permeability accompanied by inflammation in atherosclerosis. J. Clin. Investig. 2018, 128, 1106–1124.

9. Li J, Liu C.-H, Xu D.-L,Gao B. Significance of CD163-Positive Macrophages in Proliferative Glomerulonephritis. Am. J. Med. Sci. 2015, 350, 387–392.

10. Olmes G, Buettner M, Ferrazzi F, Distel L.V, Amann K, Daniel C. CD163+ M2c-like macrophages predominate in renal biopsies from patients with lupus nephritis. Arthritis Res. Ther. 2016, 18, 90

11. Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL et al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: A correlative study from the E2496 Intergroup trial. Blood. 120:3280–3287. 2012

12. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 362:875–885. 201

13. Yoon DH, Koh YW, Kang HJ, Kim S, Park CS, Lee SW et al. CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. Eur J Haematol. 88:292–305. 2012

14. Al Sayed Ahmed H, Raslan W.F, Deifalla A.H.S, Fathallah M.D. CD163 is a predictive biomarker for prognosis of classical Hodgkin's lymphoma in Saudi patients Mol Clin Oncol. 2019 Jul; 11(1): 67–76.

15. Gupta S, Yeh S, Chami R, Punnett A, Chung C. The prognostic impact of tumour-associated macrophages and Reed-Sternberg cells in paediatric Hodgkin lymphoma European Journal of Cancer Volume 49, Issue 15, October 2013, Pages 3255-3261

16. Azambuja D, Natkunam Y, Biasoli I, Lossos IS, Anderson MW, Morais JC et al. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol. 2012 Mar;23(3):736-742.

___

Vancouver Yalçın Ö. , Türkkan E. , Karabıyık Altıok D. Çocukluk Çağı Hodgkin Lenfomalarında CD163 Ekspresyonunun Prognostik Önemi. Maltepe Tıp Dergisi. 2022; 14(1): 7-10.